financetom
Business
financetom
/
Business
/
Form 8.3 - Spirent Communications PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Spirent Communications PLC
Oct 16, 2025 2:21 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Spirent Communications PLC ( SPNUF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

15-10-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

3 1/3p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

13,081,661

2.21

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

13,081,661

2.21

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

3 1/3p ordinary

equity swap

decreasing a long position

174350

198.80

3 1/3p ordinary

equity swap

decreasing a long position

620

199.20

3 1/3p ordinary

equity swap

decreasing a long position

620

199.40

3 1/3p ordinary

equity swap

increasing a long position

87072

198.80

3 1/3p ordinary

equity swap

increasing a long position

32480

199.00

3 1/3p ordinary

equity swap

increasing a long position

2365

199.10

3 1/3p ordinary

equity swap

increasing a long position

4520

199.20

3 1/3p ordinary

equity swap

increasing a long position

1154

199.40

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

3 1/3p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

13,081,661

2.21

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

13,081,661

2.21

0

0.00

0

Class of relevant security:

 

3 1/3p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

13,081,661

2.21

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

13,081,661

2.21

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dow, X-Energy Reactor Submit Building Permit Application for Texas Nuclear Plant Project
Dow, X-Energy Reactor Submit Building Permit Application for Texas Nuclear Plant Project
Mar 31, 2025
08:59 AM EDT, 03/31/2025 (MT Newswires) -- Dow (DOW) and X-Energy Reactor said Monday they have submitted a construction permit application to the Nuclear Regulatory Commission for a proposed advanced nuclear reactor in Seadrift, Texas. The proposed advanced small modular reactor project is being developed by Dow's Long Mott Energy to provide Dow's Seadrift Operations manufacturing site electrical power and...
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Mar 31, 2025
Vaxcyte Inc. ( PCVX ) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc’s Prevnar 20 (PCV20) in healthy infants. The company has selected the VAX-24 Mid-dose as the basis for advancing an optimized...
Nouveau Monde Graphite 2024 Net Loss Widens
Nouveau Monde Graphite 2024 Net Loss Widens
Mar 31, 2025
08:58 AM EDT, 03/31/2025 (MT Newswires) -- Nouveau Monde Graphite ( NMG ) was 2.7% higher at last look Monday in NYSE pre-market trading after reporting a higher net loss for 2024, but a narrower loss per share. The company reported a 2024 net and comprehensive loss of $73.3 million, or $0.71 per share, compared to a 2023 net and...
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment
Mar 31, 2025
08:59 AM EDT, 03/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting. The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B....
Copyright 2023-2026 - www.financetom.com All Rights Reserved